ONTY and CLDX announced they have initiated a combined clinical trial of ONT-10 and varlilumab. NPSP announced the company has initiated a global registration study of teduglutide in pediatric patients.

There is a critical medical need for Bioniche's technology in a $1 billion market virtually free of real competition, which opens the door for massive revenue growth, while the sound financials limits downside risk. Overall, today's $0.20 share price appears to me as an excellent entry point...